Daniel P. Petrylak, MD, provides an overview of immunotherapy treatment options for non-muscle invasive bladder cancer (NMIBC) including BCG, intravesical therapies, and checkpoint inhibitors. He also discusses clinical trials investigating alternative immunotherapy options for NMIBC other than BCG.
Read More
Daniel P. Petrylak, MD, discusses the potential role of PARP inhibitors in metastatic castration-resistant prostate cancer (mCRPC) treatment. He also discusses the two methods for approaching combination therapy with PARP inhibitors: hypoxia and the anti-androgen blockade.
Read More
Daniel P. Petrylak, MD, discusses current evidence on various pathways to target when treating metastatic urothelial cancer. He reviews agents targeting the FGFR-3 and VEGF pathways, as well as two new monoclonal antibodies, enfortumab vedotin and sacituzumab govitecan.
Read More
Daniel P. Petrylak, MD, reviews data regarding currently-approved immunotherapy agents for bladder cancer in first- and second-line settings. He advocates for future research regarding immunotherapy-based combinations, as well as investigating immunotherapy in earlier stages of the disease.
Read More
Daniel P. Petrylak, MD, discusses patient selection for currently-approved immunotherapies for prostate cancer, especially in patients with microsatellite instability. He also emphasizes the importance of utilizing immunotherapy early in the disease course.
Read More